Dr Reddy's Lab is currently trading at Rs. 1561.35, up by 6.55 points or 0.42% from its previous closing of Rs. 1554.80 on the BSE.
The scrip opened at Rs. 1564.55 and has touched a high and low of Rs. 1566.90 and Rs. 1550.60 respectively. So far 32412 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1855.00 on 09-Dec-2010 and a 52 week low of Rs. 1387.00 on 22-Aug-2011.
Last one week high and low of the scrip stood at Rs. 1654.80 and Rs. 1540.00 respectively. The current market cap of the company is Rs. 26360.71 crore.
The promoters holding in the company stood at 25.61% while Institutions and Non-Institutions held 40.74% and 15.99% respectively.
Pharma major Dr Reddy's Laboratories has appealed the government (govt) to denotify its Special Economic Zone (SEZ) at Medak in Andhra Pradesh. The formulations unit, which was to come up at Medak, will now be now shifted to Visakhapatnam where the company has another SEZ for manufacturing Active Pharmaceutical Ingredients (APIs) as the company wants to locate both its SEZs close together. The company is expected to invest around $200 million in both the SEZs.
Dr Reddy's had acquired around 103 hectares at Melasangam and Lingampally villages in Medak to set up a tablets and capsules manufacturing unit for exports. In Vizag, it had acquired around 260 acres for the bulk drugs SEZ, which will now house the formulation SEZ as well. However, the company despite shifting the formulation unit will retain the piece of land acquired at Medak and use it for other expansion plans.
The pharma company has given an undertaking to the Commerce Ministry for refunding the duty benefits availed of in the name of SEZ and the Development Commissioner of VSEZ has recommended the proposal. Further, the company is expected to take the matter for approval in the meeting of board of directors scheduled to be held on November 28, 2011.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1808.50 |
| Dr. Reddys Lab | 1342.45 |
| Cipla | 1472.45 |
| Lupin | 2147.55 |
| Zydus Lifesciences | 973.90 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
